TY - JOUR T1 - Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. AU - Payne,Daniel C, AU - Boom,Julie A, AU - Staat,Mary Allen, AU - Edwards,Kathryn M, AU - Szilagyi,Peter G, AU - Klein,Eileen J, AU - Selvarangan,Rangaraj, AU - Azimi,Parvin H, AU - Harrison,Christopher, AU - Moffatt,Mary, AU - Johnston,Samantha H, AU - Sahni,Leila C, AU - Baker,Carol J, AU - Rench,Marcia A, AU - Donauer,Stephanie, AU - McNeal,Monica, AU - Chappell,James, AU - Weinberg,Geoffrey A, AU - Tasslimi,Azadeh, AU - Tate,Jacqueline E, AU - Wikswo,Mary, AU - Curns,Aaron T, AU - Sulemana,Iddrisu, AU - Mijatovic-Rustempasic,Slavica, AU - Esona,Mathew D, AU - Bowen,Michael D, AU - Gentsch,Jon R, AU - Parashar,Umesh D, Y1 - 2013/03/13/ PY - 2013/3/15/entrez PY - 2013/3/15/pubmed PY - 2013/12/16/medline KW - New Vaccine Surveillance Network KW - RotaTeq KW - rotavirus KW - vaccine SP - 13 EP - 20 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 57 IS - 1 N2 - BACKGROUND: We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children. METHODS: We enrolled children <5 years of age hospitalized or visiting the ED with AGE symptoms from November 2009-June 2010 and from November 2010-June 2011 at 7 medical institutions. Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped. Vaccination among laboratory-confirmed rotavirus cases was compared with rotavirus-negative AGE controls. Regression models calculated VE estimates for each vaccine, age, ethnicity, genotype, and clinical setting. RESULTS: RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%-88%) and 70% (95% CI, 39%-86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (95% CI, 70%-84%) and 86% (95% CI, 74%-91%), respectively. RV1 was 78% (95% CI, 46%-91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against each of the predominant strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 VE was statistically significant for the most common genotype, G3P[8]. CONCLUSIONS: Both RV5 and RV1 significantly protected against medically attended rotavirus gastroenteritis in this real-world assessment. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/23487388/Effectiveness_of_pentavalent_and_monovalent_rotavirus_vaccines_in_concurrent_use_among_US_children_<5_years_of_age_2009_2011_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cit164 DB - PRIME DP - Unbound Medicine ER -